CSL Behring Licenses Phase III Haemophilia B Gene Therapy Candidate from uniQure
By Sasha Yachu & Michelle Liu
Pharma Deals Review: Vol 2020 Issue 7 (Table of Contents)
Published: 29 Jul-2020
DOI: 10.3833/pdr.v2020.i7.2551 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to grow its gene therapy footprint, CSL Behring has agreed to acquire the global licensing rights to commercialise uniQure’s Phase III gene therapy programme, AMT-061 (etranacogene dezaparvovec), for the treatment of haemophilia B...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS